Junshi Biosciences Reports Strong Interim Financial Results
SHANGHAI, Aug. 26, 2025 - Junshi Biosciences Co., Ltd, a trailblazer in biopharmaceutical innovation, has recently disclosed its 2025 interim financial results while providing significant updates about its company strategies. Junshi Biosciences focuses on the creative development and commercialization of pioneering therapies aimed to address critical medical needs.
Financial Highlights
As of the midpoint of 2025, Junshi Biosciences has displayed remarkable financial growth. The total revenue reached approximately RMB1,168 million during the first half of the year, reflecting an astounding increase of around 49% when compared to the previous year, largely fueled by the success of its pharmaceutical sales. The domestic sales of its flagship product, TUOYI (toripalimab), skyrocketed to about RMB954 million, marking a 42% rise from the same period in 2024.
Research and Development Investments
The company’s commitment to innovation is evident in its research and development (R&D) expenditures. In the first half of 2025, R&D costs totaled approximately RMB745 million, a 36% surge relative to the previous year. This increase underscores the company's dedication to enhancing its competitive edge through innovative R&D initiatives and aggressive clinical development.
Profit Trends
Junshi Biosciences also reported a decrease in losses attributable to the owners of the company, which fell to RMB413 million, a reduction of approximately RMB232 million or 36% from 2024. This positive trend marks an encouraging step towards the company’s path to profitability.
Cash Flow and Liquidity Position
In terms of financial stability, the first half of 2025 saw a net cash inflow from financing activities approximating RMB1,386 million. This was primarily due to the successful placement of new H shares on June 20, 2025, which generated an inflow of about RMB940 million. This influx effectively balanced out operating and investing cash outflows, reinforcing the company’s liquidity with total bank balances and cash and financial products amounting to approximately RMB3,490 million.
Strategic Business Developments
Moving beyond financial metrics, Junshi Biosciences has remained steadfast in its mission to meet unmet medical needs through innovation. The company reported numerous significant achievements and milestones that demonstrate its strategic commitment to advancing healthcare solutions.
Pipeline Advancements
Junshi Biosciences is expanding its R&D horizons beyond monoclonal antibodies to include various drug modalities. These encompass small molecule drugs, antibody-drug conjugates, and innovative therapies targeting cancer and autoimmune diseases. This diversified focus is evident with four commercialized drugs - TUOYI, JUNMAIKANG, MINDEWEI, and JUNSHIDA - and about 30 assets currently in clinical trials.
Regulatory Approvals and New Drug Applications
This year has also proven fruitful for regulatory advancements. In January, the NMPA approved significant indications for TUOYI and MINDEWEI, moving from conditional to regular approvals. Furthermore, various new drug applications have been accepted and approved, showcasing the company’s growing influence in both domestic and international markets.
Collaborations and Partnerships
The company actively pursues collaborations to expedite its market reach. A notable agreement was established with LEO Pharma in January 2025, allowing LEO Pharma exclusive rights to distribute and market toripalimab across the EU and UK. This partnership demonstrates Junshi's ambitions to enhance its product's global presence.
About Junshi Biosciences
Founded in December 2012, Junshi Biosciences is pioneering innovative biopharmaceuticals with a robust pipeline of over 50 drug candidates. Their therapeutic focus spans across cancer, autoimmune disorders, metabolic issues, neurological conditions, and infectious diseases. The company is particularly proud of toripalimab, China's first domestically developed anti-PD-1 monoclonal antibody, which has received approvals from numerous countries, including the US and regions across Europe.
Junshi Biosciences Contact Information
For more inquiries:
IR Team: Junshi Biosciences
Email: info@junshipharma.com
Phone: +86 021-6105 8800
Frequently Asked Questions
1. What were the financial achievements of Junshi Biosciences in 2025?
Junshi Biosciences reported a revenue increase of about 49%, reaching approximately RMB1,168 million, with core product sales significantly contributing to this growth.
2. How much did Junshi Biosciences invest in R&D in the first half of 2025?
In the first half of 2025, the company spent approximately RMB745 million on R&D, reflecting a 36% rise compared to the previous year, emphasizing their commitment to innovation.
3. What is the status of Junshi's product pipeline?
The product pipeline includes four commercialized drugs and approximately 30 assets in clinical trials, showcasing a diverse approach to drug development.
4. What significant partnerships has Junshi Biosciences established recently?
Junshi entered a distribution agreement with LEO Pharma to market toripalimab in the EU and UK, enhancing their global product reach.
5. How does Junshi Biosciences contribute to addressing global health needs?
Junshi actively develops innovative therapies targeted at unmet medical needs, specifically in the areas of cancer and infectious diseases, impacting healthcare positively.
